4585 related articles for article (PubMed ID: 28585211)
1. Non-Alcoholic Fatty Liver Disease.
Engin A
Adv Exp Med Biol; 2017; 960():443-467. PubMed ID: 28585211
[TBL] [Abstract][Full Text] [Related]
2. Experimental Nonalcoholic Steatohepatitis and Liver Fibrosis Are Ameliorated by Pharmacologic Activation of Nrf2 (NF-E2 p45-Related Factor 2).
Sharma RS; Harrison DJ; Kisielewski D; Cassidy DM; McNeilly AD; Gallagher JR; Walsh SV; Honda T; McCrimmon RJ; Dinkova-Kostova AT; Ashford MLJ; Dillon JF; Hayes JD
Cell Mol Gastroenterol Hepatol; 2018 Mar; 5(3):367-398. PubMed ID: 29552625
[TBL] [Abstract][Full Text] [Related]
3. Free radical biology for medicine: learning from nonalcoholic fatty liver disease.
Serviddio G; Bellanti F; Vendemiale G
Free Radic Biol Med; 2013 Dec; 65():952-968. PubMed ID: 23994574
[TBL] [Abstract][Full Text] [Related]
4. Methionine restriction prevents the progression of hepatic steatosis in leptin-deficient obese mice.
Malloy VL; Perrone CE; Mattocks DA; Ables GP; Caliendo NS; Orentreich DS; Orentreich N
Metabolism; 2013 Nov; 62(11):1651-61. PubMed ID: 23928105
[TBL] [Abstract][Full Text] [Related]
5. n-3 Polyunsaturated fatty acids for the management of alcoholic liver disease: A critical review.
Wang M; Ma LJ; Yang Y; Xiao Z; Wan JB
Crit Rev Food Sci Nutr; 2019; 59(sup1):S116-S129. PubMed ID: 30580553
[TBL] [Abstract][Full Text] [Related]
6. The role of hepassocin in the development of non-alcoholic fatty liver disease.
Wu HT; Lu FH; Ou HY; Su YC; Hung HC; Wu JS; Yang YC; Wu CL; Chang CJ
J Hepatol; 2013 Nov; 59(5):1065-72. PubMed ID: 23792031
[TBL] [Abstract][Full Text] [Related]
7. Decoding cell death signals in liver inflammation.
Brenner C; Galluzzi L; Kepp O; Kroemer G
J Hepatol; 2013 Sep; 59(3):583-94. PubMed ID: 23567086
[TBL] [Abstract][Full Text] [Related]
8. Pathogenesis of NASH: How Metabolic Complications of Overnutrition Favour Lipotoxicity and Pro-Inflammatory Fatty Liver Disease.
Farrell GC; Haczeyni F; Chitturi S
Adv Exp Med Biol; 2018; 1061():19-44. PubMed ID: 29956204
[TBL] [Abstract][Full Text] [Related]
9. Ectopic lipid accumulation: A potential cause for metabolic disturbances and a contributor to the alteration of kidney function.
Guebre-Egziabher F; Alix PM; Koppe L; Pelletier CC; Kalbacher E; Fouque D; Soulage CO
Biochimie; 2013 Nov; 95(11):1971-9. PubMed ID: 23896376
[TBL] [Abstract][Full Text] [Related]
10. The ménage à trois of autophagy, lipid droplets and liver disease.
Filali-Mouncef Y; Hunter C; Roccio F; Zagkou S; Dupont N; Primard C; Proikas-Cezanne T; Reggiori F
Autophagy; 2022 Jan; 18(1):50-72. PubMed ID: 33794741
[TBL] [Abstract][Full Text] [Related]
11. Attenuated lipotoxicity and apoptosis is linked to exogenous and endogenous augmenter of liver regeneration by different pathways.
Weiss TS; Lupke M; Ibrahim S; Buechler C; Lorenz J; Ruemmele P; Hofmann U; Melter M; Dayoub R
PLoS One; 2017; 12(9):e0184282. PubMed ID: 28877220
[TBL] [Abstract][Full Text] [Related]
12. Mitochondrial gene polymorphisms alter hepatic cellular energy metabolism and aggravate diet-induced non-alcoholic steatohepatitis.
Schröder T; Kucharczyk D; Bär F; Pagel R; Derer S; Jendrek ST; Sünderhauf A; Brethack AK; Hirose M; Möller S; Künstner A; Bischof J; Weyers I; Heeren J; Koczan D; Schmid SM; Divanovic S; Giles DA; Adamski J; Fellermann K; Lehnert H; Köhl J; Ibrahim S; Sina C
Mol Metab; 2016 Apr; 5(4):283-295. PubMed ID: 27069868
[TBL] [Abstract][Full Text] [Related]
13. Monascin and ankaflavin act as natural AMPK activators with PPARα agonist activity to down-regulate nonalcoholic steatohepatitis in high-fat diet-fed C57BL/6 mice.
Hsu WH; Chen TH; Lee BH; Hsu YW; Pan TM
Food Chem Toxicol; 2014 Feb; 64():94-103. PubMed ID: 24275089
[TBL] [Abstract][Full Text] [Related]
14. The ketogenic diet prevents steatosis and insulin resistance by reducing lipogenesis, diacylglycerol accumulation and protein kinase C activity in male rat liver.
Jani S; Da Eira D; Stefanovic M; Ceddia RB
J Physiol; 2022 Sep; 600(18):4137-4151. PubMed ID: 35974660
[TBL] [Abstract][Full Text] [Related]
15. Effects of the new thiazolidine derivative LPSF/GQ-02 on hepatic lipid metabolism pathways in non-alcoholic fatty liver disease (NAFLD).
Araújo S; Soares E Silva A; Gomes F; Ribeiro E; Oliveira W; Oliveira A; Lima I; Lima MDC; Pitta I; Peixoto C
Eur J Pharmacol; 2016 Oct; 788():306-314. PubMed ID: 27349145
[TBL] [Abstract][Full Text] [Related]
16. Myristic acid potentiates palmitic acid-induced lipotoxicity and steatohepatitis associated with lipodystrophy by sustaning de novo ceramide synthesis.
Martínez L; Torres S; Baulies A; Alarcón-Vila C; Elena M; Fabriàs G; Casas J; Caballeria J; Fernandez-Checa JC; García-Ruiz C
Oncotarget; 2015 Dec; 6(39):41479-96. PubMed ID: 26539645
[TBL] [Abstract][Full Text] [Related]
17. Niacin inhibits fat accumulation, oxidative stress, and inflammatory cytokine IL-8 in cultured hepatocytes: Impact on non-alcoholic fatty liver disease.
Ganji SH; Kashyap ML; Kamanna VS
Metabolism; 2015 Sep; 64(9):982-90. PubMed ID: 26024755
[TBL] [Abstract][Full Text] [Related]
18. Hepatocyte-specific Keap1 deletion reduces liver steatosis but not inflammation during non-alcoholic steatohepatitis development.
Ramadori P; Drescher H; Erschfeld S; Schumacher F; Berger C; Fragoulis A; Schenkel J; Kensler TW; Wruck CJ; Trautwein C; Kroy DC; Streetz KL
Free Radic Biol Med; 2016 Feb; 91():114-26. PubMed ID: 26698665
[TBL] [Abstract][Full Text] [Related]
19. TXNIP/VDUP1 attenuates steatohepatitis via autophagy and fatty acid oxidation.
Park HS; Song JW; Park JH; Lim BK; Moon OS; Son HY; Lee JH; Gao B; Won YS; Kwon HJ
Autophagy; 2021 Sep; 17(9):2549-2564. PubMed ID: 33190588
[TBL] [Abstract][Full Text] [Related]
20. Silibinin ameliorates hepatic lipid accumulation and oxidative stress in mice with non-alcoholic steatohepatitis by regulating CFLAR-JNK pathway.
Liu Y; Xu W; Zhai T; You J; Chen Y
Acta Pharm Sin B; 2019 Jul; 9(4):745-757. PubMed ID: 31384535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
